The healthcare ecosystem is rich with opportunity. Find new connection points with this business-to-ecosystem interactive tool. Explore the possibilities.
The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year.
During a press briefing, FDA officials expressed optimism the decision could help boost vaccination rates, but warned against off-label use — particularly in children, for which clinical tests are currently underway.
A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others.
Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Learn how you can overcome them.
The company's cancer cell therapy Kymriah failed to top standard care in patients with an aggressive form of lymphoma, a setting in which treatments from Bristol Myers Squibb and Gilead recently succeeded.
Aamir Malik, a managing partner at the consulting firm, will replace longtime Pfizer executive John Young as chief business innovation officer next week.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550, Washington, DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
No comments:
Post a Comment